Altogen Biosystems

Altogen Biosystems leverages its expertise in polymer-stabilized liposomes, nanoparticles, and polymer chemistry to create optimized transfection solutions for delivering biomolecules like plasmid DNA, siRNA, mRNA, and proteins. Its technology has been cited in high-impact journals including Nature, Nature Medicine, and Nature Biotechnology, validating its research applications. The company operates a dual business model, selling proprietary transfection reagents while also offering comprehensive CRO services through Altogen Labs to support drug discovery and IND-enabling studies. Its strategic focus is on enabling gene function studies and therapeutic delivery across oncology, cardiovascular, metabolic, and infectious diseases.

Develops and manufactures advanced transfection reagents using polymer-stabilized liposomes, nanoparticles, and optimized polymer chemistry for efficient delivery of DNA, RNA, and proteins into specific cell lines and tissues in vivo.

Total raised: $2M

Competes with giants like Thermo Fisher Scientific (Lipofectamine) and Promega in the broad transfection market. Differentiation is achieved through deep optimization for specific cancer cell lines, a focused suite of tissue-targeted in vivo reagents, and the unique integration with a preclinical CRO service, offering a validated end-to-end workflow for researchers.